COVID-19 Eliminating Onsite Monitoring Visits in Clinical Studies; MANA RBM Has the Immediate Remote Risk Based Monitoring Solution

March 17, 2020

MANA RBM's network of clinical researchers reported that research sites are eliminating onsite monitoring visits. If onsite monitoring visits are a Sponsor's main oversight approach, the solution to this critical problem is available now. 

MANA RBM provides remote, automated risk-based monitoring (RBM) customized to a site's protocol. The company delivers its solution, customized to the areas of greatest concern, specific to a study.  Subject review can begin within days.

"We recently published an example of this successful approach, adding remote Risk Based Monitoring to trials being conducted with traditional SDV," said Penny Manasco, M.D., CEO of MANA RBM.  "Within days, we started remote subject review. Within 2 months, we identified critical errors that SDV did not find."

Here is the link to the head to head comparison: 
http://www.appliedclinicaltrialsonline.com/comparing-risk-based-monitoring-and-remote-trial-management-vs-sdv

See the latest posts on our homepage


Share

Topic Area: Press Release


Recent Posts



Post Comment




FREE
NEWSLETTER

News & Updates • Webcast Alerts • Building Technologies

All fields are required.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.